Metropolis Healthcare Secures Patent for Advanced TB Monitoring and Management System
Mumbai, India: Ameera Shah-led Metropolis Healthcare Limited (NSE: METROPOLIS|BSE: 542650), India’s second largest and most respected pathology laboratory chain, today announced that it has been granted a patent by the Patent Office, Government of India, for its invention titled “System and Method for Monitoring and Managing Mycobacterium Species-Related Infections”.
The patented method introduces a structured, data-driven approach to support clinicians in evaluating and managing patients being assessed for tuberculosis and related mycobacterial infections.
The innovation brings together microbiology findings, molecular diagnostic results, radiology assessments, and patient-specific risk factors within an intelligent, algorithm-enabled framework. By consolidating these diverse insights into a unified pathway, the method aims to improve interpretation and promote greater consistency in clinical evaluation, particularly in settings where accuracy is critical.
Commenting on the development, Mr. Surendran Chemmenkotil, Managing Director, Metropolis Healthcare Limited, said: "This is a proud moment for Metropolis as we receive our first patent, an important milestone that reflects our continued commitment to scientific rigor and purposeful innovation in diagnostics.
The method recognized under this patent is intended to enhance TB evaluation and offer clinicians an added layer of support in complex decision pathways. As India advances toward its TB elimination goals, we hope this development contributes meaningfully, particularly in communities that face a higher burden of the disease.”
India has made meaningful progress in addressing tuberculosis under the National Tuberculosis Elimination Programme (NTEP), supported by improvements in detection, reporting and treatment outcomes. Diagnostic innovations that organize data and streamline clinical workflows play a vital role in complementing these national public health efforts.
Dr. Kirti Chadha, Chief Scientific and Innovation Officer, Metropolis Healthcare Limited, added: “Early and accurate diagnosis remains essential to improving TB outcomes.
This patented system and method has been developed with a strong scientific foundation, integrating diagnostic signals into a framework that supports clearer clinical assessment. Our aim is to provide physicians with structured, evidence-supported insights that assist in making more precise and confident decisions.”
This milestone underscores Metropolis Healthcare’s efforts to expand its innovation portfolio and apply advanced diagnostic science to areas of significant public health relevance. It also reflects the company’s commitment to contributing to national priorities such as the TB Mukt Bharat Abhiyaan through solutions designed to support more effective and timely patient care.
Stuti Tiwari joined Medical Dialogues in 2025 as a Hindi Content Writing Intern. She is currently pursuing a Bachelor’s degree in Journalism from the University of Delhi. With a strong interest in health journalism, digital media, and storytelling, Stuti focuses on writing, editing, and curating Hindi health content. She works on producing informative, engaging, and accurate articles to make healthcare news and updates more understandable and relatable for Hindi-speaking audiences.